Verdict Expected In SAC Capital's Mathew Martoma's Insider Trading Case
The 39-year-old Mathew Martoma is embroiled in what prosecutors have called the most lucrative insider trading episode in U.S. history. Martoma, who worked in SAC Capital Advisors' CR Intrinsic Investors division, is accused of using confidential information to trade stocks of the drug's developers, Elan Corp Plc and Wyeth, currently owned by Pfizer Inc.